Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
P/B ratio for Eli Lilly and Company (LLY)
P/B ratio as of 2023: 48.89
According to Eli Lilly and Company's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 48.89. At the end of 2022 the company had a P/B ratio of 30.98.
P/B ratio history for Eli Lilly and Company from 1985 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 48.89 |
| 2022 | 30.98 |
| 2021 | 27.90 |
| 2020 | 27.16 |
| 2019 | 46.94 |
| 2018 | 12.10 |
| 2017 | 7.66 |
| 2016 | 5.56 |
| 2015 | 6.14 |
| 2014 | 4.80 |
| 2013 | 3.13 |
| 2012 | 3.72 |
| 2011 | 3.42 |
| 2010 | 3.12 |
| 2009 | 4.12 |
| 2008 | 6.54 |
| 2007 | 4.26 |
| 2006 | 5.16 |
| 2005 | 5.70 |
| 2004 | 5.63 |
| 2003 | 7.75 |
| 2002 | 8.28 |
| 2001 | 11.91 |
| 2000 | 16.63 |
| 1999 | 14.44 |
| 1998 | 22.01 |
| 1997 | 16.50 |
| 1996 | 6.54 |
| 1995 | 5.89 |
| 1994 | 3.54 |
| 1993 | 3.90 |
| 1992 | 3.61 |
| 1991 | 4.89 |
| 1990 | 6.07 |
| 1989 | 5.37 |
| 1988 | 3.76 |
| 1987 | 3.68 |
| 1986 | 3.71 |
| 1985 | 3.21 |